RRE Ventures director granted warrants and founder shares
RRE Ventures Acquisition Corp. director Robert Scott Mancini reported awards of derivative securities linked to Class A Ordinary Shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
RRE Ventures Acquisition Corp. director Robert Scott Mancini reported awards of derivative securities linked to Class A Ordinary Shares. He received 250,000 warrants at $1.00 per warrant, each exercisable into one Class A share at an exercise price of $11.50 after the company’s initial business combination. He also received 75,000 and 40,000 Class B Ordinary Shares at no cost, which automatically convert into Class A shares on a one-for-one basis in connection with the initial business combination or earlier at his option.
Insider Trade Summary
Grant/Award: 365,000 shares
Grant/Award
3 txns
Insider
Mancini Robert Scott
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Warrant | 250,000 | $1.00 | $250K |
| Grant/Award | Class B Ordinary Shares | 75,000 | $0.00 | $0.00 |
| Grant/Award | Class B Ordinary Shares | 40,000 | $0.00 | $0.00 |
Holdings After Transaction:
Class B Ordinary Shares — 115,000 contracts (Direct);
Warrant — 250,000 contracts (Direct)
Footnotes (3)
- F1. The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
- F2. These securities were previously reported on a Form 3 filed by the Reporting Person.
- F3. The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination and will expire five years after the completion of the Issuer's initial business combination or earlier upon liquidation.
Key Figures
Warrant grant size: 250,000 warrants
Warrant grant price: $1.00 per warrant
Warrant exercise price: $11.50 per share
+5 more
8 metrics
Warrant grant size
250,000 warrants
Grant of private placement warrants to director
Warrant grant price
$1.00 per warrant
Grant price for 250,000 warrants
Warrant exercise price
$11.50 per share
Exercise price into Class A Ordinary Shares
Underlying Class A shares (warrants)
250,000 shares
Underlying Class A Ordinary Shares for warrants
Class B grant on March 25, 2026
75,000 shares
Class B Ordinary Shares, convertible 1-for-1 to Class A
Class B grant on March 20, 2026
40,000 shares
Class B Ordinary Shares, convertible 1-for-1 to Class A
Class B holdings after March 25 grant
115,000 shares
Total Class B Ordinary Shares following that transaction
Warrant holdings after grant
250,000 warrants
Total warrants following latest transaction
Key Terms
Class B Ordinary Shares, Class A Ordinary Shares, private placement warrants, initial business combination, +1 more
5 terms
private placement warrants financial
"The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination"
Private placement warrants are tradable coupons given directly to a limited group of investors that let the holder buy a company's shares at a fixed price before a set expiration date. They matter to investors because they can provide extra upside if the stock rises and give companies a way to raise money outside a public offering, but they also can increase the number of shares outstanding (dilution) and therefore affect share value and investor returns.
initial business combination financial
"The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination"
An initial business combination is the deal in which a special-purpose acquisition company (SPAC) merges with or acquires an operating business to bring that business onto public markets. Think of the SPAC as an empty shell that raises money from investors, then uses that cash to buy a private company—this transaction turns the private company into a public one and often changes its ownership, valuation, and access to capital, so investors should watch for shifts in risk, future growth prospects, and shareholder rights.
Form 3 regulatory
"These securities were previously reported on a Form 3 filed by the Reporting Person."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Mancini report for RRE Ventures Acquisition Corp. (RREVU)?
Robert Scott Mancini reported awards of derivative securities, including 250,000 warrants and additional Class B Ordinary Shares. These grants increase his potential exposure to Class A Ordinary Shares but do not involve any open-market purchases or sales of the company’s stock.
How many warrants did Mancini receive in the latest RRE Ventures (RREVU) Form 4?
Mancini received 250,000 warrants at a grant price of $1.00 per warrant. Each warrant is exercisable into one Class A Ordinary Share at an exercise price of $11.50, becoming exercisable after the issuer completes its initial business combination.
Do Mancini’s RRE Ventures (RREVU) transactions involve any stock sales?
The reported transactions are all acquisitions coded as grants or awards, with no sales disclosed. They consist of warrants and Class B Ordinary Shares that provide potential future equity exposure rather than immediate open-market buying or selling activity.
When do Mancini’s private placement warrants in RRE Ventures (RREVU) become exercisable?
According to the footnotes, the private placement warrants become exercisable 30 days after completion of the issuer’s initial business combination. They will then remain outstanding for five years after that business combination, unless the company liquidates earlier.
AI-generated analysis. How Rhea-AI works. Not financial advice.
